World J Urol (2017) 35:1261–1268 DOI 10.1007/s00345-016-1988-y ORIGINAL ARTICLE Randomized, double‑blind, placebo‑controlled trial to compare solifenacin versus trospium chloride in the relief of double‑J stent‑related symptoms 1 2 1 Mohamed H. Abdelhamid · Ahmed S. Zayed · Waleed E. Ghoneima · 3 1 3 3 Akrm A. Elmarakbi · Mohamed S. El Sheemy · Ahmed Aref · Ahmed Abdelbary · Hani H. Nour Received: 19 September 2016 / Accepted: 4 December 2016 / Published online: 3 January 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract mean scores across all groups. Drug-related side effects, Purpose We aimed to compare the safety and efficacy of particularly constipation, were higher in trospium group solifenacin versus trospium chloride and compare each than in solifenacin one. drug versus placebo regarding the relief of stent-related Conclusions Solifenacin treatment showed significant symptoms following uncomplicated ureteroscopic litho- improvement in almost all domains of stent-related symp- tripsy (URSL). toms than trospium. In terms of safety and tolerance, both Methods In a prospective, randomized, double-blind study, drugs were comparable. Future studies should be designed 210 eligible patients who underwent URSL with double- to address the impact of combined drugs and lower doses in J stent insertion were recruited and randomly
World Journal of Urology – Springer Journals
Published: Jan 3, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera